CME: Multiple Myeloma (MM): Highlights from the American Society for Clinical Oncology (ASCO) 2018
ACCREDITATION EXPIRED: July 19, 2020
Activity Description / Statement of Need:
In this online, self-learning activity:
Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners. ASCO 2018 is no exception. Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting.
Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus. While MM only makes up about 1% of all cancers, it the most common of the blood cancers with an incidence of a little under 31,000 and an annual mortality rate of just under 13,000. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites.
Target Audience:
The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.
This program is supported by educational grants from Amgen.
Release Date: July 19, 2018 -- Expiration Date: July 19, 2020
Faculty: Ravi Vij, MD MBA
Agenda
|
Faculty member introduction, disclosures |
|
Major findings from ASCO 2018 related to Multiple Myeloma, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice |
|
Application: patient cases |
|
Summary, conclusion, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize the most impactful findings presented at ASCO 2018 Meeting related to multiple myeloma
- Review data on CAR-T cell therapy for multiple myeloma
- Update on status of check-point inhibitors in multiple myeloma
- Recall the findings from the latest phase 3 studies of proteosome inhibitors in multiple myeloma
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Ravi Vij, MD, MBA, Washington University School of Medicine, St. Louis, MO, has received financial compensation from participation at advisory boards and/or research grants from Amgen, BMS, Celgene, Takeda, Janseen, Kargopharma, and Jazz.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Amgen.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.